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The effect of co-inoculation of membrane matrix, Matrigel and two human breast cancer
cell lines, BT-474 and SK-BR-3, was tested in immune-deficient mice. Both cedl ines strongly o
c-ErbB-2 protein, whers only BT-474 is reported to be oestrogInrptor positive. Co-inoculation of
Matnrg and BT-474 cells but not of MatriFg and SK-BR-3 cell resulted tumour formatin in bg-nu-xid
mice. Otrogen s ementation greatly hanced tumorigecty, but did not seem to be an absolute
In vivo, BT474 cells grow as a poorly differentiated with a doubling timc of
9.4 1.1 days after inoculation into the nek regkoL A high proliferative activity appears to beco
by a relatvely high rate of cdl loss, as BT-474 tumours contam many ceils with the typical morphology of
apoptotic cell death. Wild-type p53, known to participate in the inductin of apoptosis, is absent from the
tumours, whereas Bd-2, known to inhibit apoptosis, is expresse at interediate kvels, BT-474 tumours tend
to mttasase to the regonal lymph nodes and are of formming eastatic lesions m the hmg.
Flow cytometical nalysis of DNA ploidy no change in tmmours compared with the cell hne.
Immunohistochemical and flow cytometical detection of a number of hormone and growth factor rceptors,
cell adhson molecules and proteins invohled in proliferation and cal death demon-
strated no major chang in ploidy and phenotype of tumours compared with the cell ine. High expression of
the cell-surface molcules c-ErbB-2 and epialin make it a potentially useful model for research in immune
therapy.
werwoi. brast cancer, immune-deficnt mice; Matngel; tumongemcity; oestrogen receptor, c-erbB-2
Heterotransplantation of human cancers into immune-
deficient mice can be used to test various anti-cancer
therapies (Giovanella et al., 1978; Sebesteny et al., 1979). For
a number of tumour types, such as colon cancer, melanoma
and pancreatic cancer, orthotopic implantation of primary
tumours in these animals has been reported to improve
significntly both take rate and expression of metastatc
phenotype (Cornil et al., 1989; Fu et al., 1991, 1992).
Primary breast cancer, however, lacks tumorigenicity, even
when implanted orthotopically. Primary tumours that do
grow in immune-deficient mice are predominantly of the
hormone-independent phenotype. Furthermore, only a min-
onty of established breast cancer cel lines are oestrogen
receptor (ER) positive (Fogh et al., 1977). At present, in
vivo/in vitro studies of hormone-dependent breast cancer
largely depend on the MCF-7, T47D and ZR-75-1 cell lines
(Shafie and Liotta, 1980, Leung and Shiu, 1981; Weckbecker
et al., 1992; Yue and Brodie, 1993). These cell lines have
been established from pleural effusions and are tumorigenic
in oestrogen-suppkmented immundicient mice.
Recently it has been reported that co-inoculation of
dispersed primary tumours or of cultured tumour cels with
Matrigel or fibroblasts enhas tumour take and growth of
various types of cancer in immune-deficient mice (Horgan et
al., 1987; Fridman et al., 1990, 1991, 1992; Chung, 1991;
Pretlow et al., 1991; Albini et al., 1992; Noel et al., 1992;
Paaniti et al., 1992; Mehta et al., 1993; Sterling-Levis et al.,
1993; Topley et al., 1993; Yue and Brodie 1993; Bao et al.,
1994). The aim ofthe present study was therefore to evaluate
whether this approach would increase the take rate of breast
cancer cell lnes known to show little or no tendency to
produce tumours in these mice. For this purpose two human
breast cancer cell lines were selected, SK-BR-3 and BT-474,
the latter (isolated in 1976 from a sold invasive ductal
carcinoma; Lasfargues et al., 1978) reported to be ER
positive (Lupu and Lippman, 1993).
A emnarkable feature of these cell ies is that they show
strong c-erbB-2 oncogene overexpresson; c-erbB-2 is overex-
pr 2- to 30-fold in 30% of human breast cancers
(Elledge et al., 1992) and has been reported to be an impor-
tant prognostic factor in node-negative breast ancer (Pavelic
et al., 1992). Stable and exclusive c-erbB-2 overexpression by
malignant cells (Niehans et al., 1993) and profound effects of
signal transduction through the c-ErbB-2 pathway (Harwerth
et al., 1993; Lupu and Lippman 1993) make this receptor
protein an interesting target for immunotherapy (Hynes,
1993). Therefore, we believe that hormone-reponsive o ivo
models with c-erbB-2-overexpressing human breast cancer
cells would be useful in the development of novel therapies
for breast cancer.
In this report we described formation of tumours from
BT-474 cells in immune-deficient mice supplemented with
oestrogen. We compared take rates of orthotopically and
subcutaneously inoculated tumour cells and evaluated growth
kinetics and metastatic behaviour. Apart from expression of
c-ErbB-2 protein and oestrogen receptor in BT-474 cells, we
analysed DNA ploidy, cell cycling activity and apoptosis and
expression of al growth factor receptor, progesterone
receptor, various adhesion moeules, tumour marers and
oncogenes, comparing BT-474 tumours with cultured cells.
Materials and
Animals
Female bg-nu-xid homozygous mice, 4-5 weeks ol, were
obtined from Harlan Sprague Dowley (Indianapolis, IN,
USA) and Charles River Laboratories (Boston, MA, USA).
These mice lack natural killer cell activity owing to the beige
(bg) mutation, are athymic owing to the nude mutation (nu)
and have a lack ofT cell-independent B cells because of their
X-linked immun deficiency. The animals were kept in
isolator cages which were changed twice weekly. They were
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February 1995fed with gamma-irradiated rodent food and water ad libitmn
and handled under laminar flow biocontainment to prevent
contamination.
Cel lins
The SK-BR-3 and BT-474 cell lnes were kindly provided by
Dr Christopher C Benz (Cancer Research Institute, UCSF,
CA, USA). Cells were maintained in RPMI-1640 medium
(Sigma, St Louis, MO, USA) pmented with L-gUtamue
and 10% fetal bovine serum (Sigma). The cultures were
harvested for passage weekly. Fibroblasts were obtaind by
parially trypsnising short-term cultures of human primary
breast tumours or normal skin.
Site of noculation
Monolayers were trypsnised and a standard dose of 2 x 10'
cells was inoculated into bg-nu-xid mice at three different
sites: (1) subcutaneously into the neck region, (2) into the
anterior mammary fat pad and (3) into the posterior mam-
mary fat pad. Twice weekly the mice were inspected and
tumours measured with calpers; vohlme was calulated using
the formula (1) x (w) x (h) x 0.52 = tumour volume (mm3).
hnculaion with Matrigel
Matrigel (Collaborative Resarch, Bedford, MA, USA) was
aliquoted and thawed acording to the manufac r's
instructions. To prevent Matrigel from lling, all pipettes,
syringesneedles and centrifu tubes were chilled on ice
before use. After trypsnisation, the number of viable cells
was detemined in a trypan bue exdusion test using a
haemocytometer. Cells were pelkled, iesuspended in med-
ium-MatriSe (50:50) and injected.
Hormone supplementation
Oestrogen was suppled to the animals using subcutaneous,
sustained-relese (60 days) pellets, containing 0.72mg of
oestrogen (IRA, Toledo, OH, USA). Pellets were impanted
using a 10 gauge trocar.
Steroidhormone receptor assays
ER Enzyme Immuno Assay (Abbott Diagnostics Division,
North Chicago, IL, USA) was performed at the Division of
Endocrine Oncology, Dr Daniel den Hoed Cancer Center
(Rotterdam, The Netherlands), usng the Abbott ER-EIA
monoclonal kit. ER ligand-binding assay was performed at
the Division of Experimental and Chemical Endocrinology,
St Radboud Hospital (Nijmegen, The Netherlands), using the
dextran-coated charcoal method and multiple point technique
as recommended by the EORTC (Anon, 1980).
Flow cytometry
Cells were detached usng 5 ml of Hanks' balanced salt solu-
tion (HBSS; Gibco, Grand Island, NY, USA) contaning
0.25% trypsin (Flow Laboratories, Irvine, UK) and 4mM
EDTA (JT Baker, Deventer, The Nethrlands). After washes
in phosphate-buffered saline with 0.5% bovine serm
albumin (PBS/BSA, Sigma) cells were filtered over a 50nm
nylon gauze (Versidag-Industrietextilien, Kempen, Ger-
many). With the trypan blue exclusion assay, cell yield and
viability were calculated, so that each sample contained
0.5-1 x 10 viable cells. Staining was done according to the
protocol of Corver et al. (1994). Briefly, for staining of
membrane-associated antigens, cells were fixed with 1/%
paraformaldehyde and permeabilised with 40jag of L<-
lysophosphatidykholine (Sigma) per 10' cels (10 min at 4-C).
Depending on loalisation of the antigen at the inner or
outer membrane, cells were fixed and permeabilsed before or
after incubation with primary and secondary antibody
respectively. For ining of antis locaised in the cytosol
BT474 kudcr~e gml p mdIin b=P gfk nk
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or nucleus, cells were fixed with 1% paraformaldehyde
(5min at 4-C) followed by 100% methanol (10min at
-20C). Incubation with primary monoclonal antibodies
(30min on ice), was followed by another 30min incubation
with fluorescein isothiocyanate (FITC)- or R-phycoerythrin
(RPE)-labelled isotype-specific, goat anti-mouse antibody
(GAM; Souther Biotechnology Associates, Birmingham,
AL, USA). Monoclonal antibodie used are listed in Table
IH. Control samples were incubated with PBS alone and
isotype-secific secondary antibodies alone. Samples were
measured on a FACScan flow cytometer (Becton Dickinson,
San Jose, CA, USA). FITC and propidium iodide (Sigma)
fluorescene was measured using, r ely, a 530/30 nm
(FLI) and a 585/42 mm (F12) bandpass filter and a minimum
of 10000 events were counted. The CellFit software was used
for double-fluorescence measurement of DNA and MIB-1 or
PCIO antigens respectively.
DNA ploidy
The DNA index from frozen sections and paraffin-embedded
tissue was determined using the methods described by
Vindelov et al. (1983) and Hedley et al. (1983). Chicken red
blood cells (CRBCs) were added to each sample as a
reference. The DNA index (defined as human aneuploid
G0.//human diploid Goll) of BT-474 cells was calculated using
the ratio human diploid G11 peak/CRBC. Samples were
measured on a FACScan flow cytometer (Becton Dickinson)
and analysed using MODFIT software (Verity Software
House, Topsham, ME, USA).
Immunohistochemistry
To compare expression of antigens in BT-474 tumours with
flow cytometical analysis of the cell line, frozen sections of
tumour were fixed according to the protocol used for flow
cytometry. Standard DAB staining with biotinylated goat
anti-mouse bridging antibody (Becton Dickinson) and strept-
avidin-biotinylated horseradish peroxidase complex (Becton
Dickinson) was used for detection of bound primary
antibodies. Methyl green dye was used for background stain-
ing.
ER, Ki-67, PCNA andkeratin staining ofparaffin-embedd
tissue
Two micron praffin sections were mounted on Starfrost
tissue section slides (Knittel Gliser, Braunschweig, Ger-
many), dried overnight at room temperature and depara-
ffinisd Subsequently, ER was stained usng the Abbott kit
(Abbott Diagnostics Division) and Novocastra kit (Novocas-
tra Laboratories, Newcastle upon Tyne, UK). For Ki-67,
proliferating cel nuclear antigen (PCNA) and keratin stain-
ing endogenous peroxidase was blocked with
methanol-0.3% hydrogen peroxide (20min). Sections were
boied in 2 x SSC* (20mi; Ki-67) or citrate buffer (20min
PCNA) or microwaved (30min, 90-C; keratin) and cooled
overnight. For blocking non-specific background staining,
slides were incubated with phosphate-buffered saline (PBS)
10% normal goat senim (NGS) (20min at room
temperature)with subsequent use of avidin/biotin blocking
kit (Vectr Laboratories, Budingame, CA, USA). Sections
were then incubated with primary antibody (1:40) for 1 h.
Standard DAB staining with biotinylated goat anti-mouse
bridging antibody (Becton Dickinson) and strep-
taviin-biotinylated horadish peroxidase complex (Becton
Dickinson) was used for detection of bound primary
antibodies. Haematoxylin was used as background stain. The
percent of Ki-67 positive cells was quantitated by coun-
ting a total of 1000 cells in every section.
ISEL staning apoptotic celis
A modification of the in situ end-labelling technique des-
cribed by Wijsman et al. (1993) was used for staining ofBT-474 lru7- c l ad g in...dddinM mIc
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apoptotic cells in paraffin sections from BT-474 tumours. The
number of stained cells in each section was quantitated usng
the automated image analysis system CAS-200D (Becton
Dickinson). We used a 40 x Planachro objective and appled
a program normaly used for analysis of immunohisto-
chemically stained proliferating cell nuclear antigen (PCNA).
Res
Effect ofMatrigel, hormone supplementation and inoculation
site on tunourformatin ofBT-474 andSK-BR-3 cells in
une-kfient mice
Experimental groups are summarised in Table I. The stan-
dard dose of inoculation used for tumour cell lines in these
experiments was 2 x 10' cells and all animals were injected
subcutaneously both in the neck and in the posteior mam-
mary fat pad. None of the snimals injected with tumour cells
alone developed tumours (a minimal follow-up period of 100
days). Only one animal inculated with BT-474 cells together
with Matrigel developed a progressively growing tumour in
the neck (Table I and Figure la). However, as shown in
Figure Ib, oestrogen supplmentation invariably resulted in
Tak I Take rate ofBT-474 and SK-BR-3 cells in immune-defi t
Anima with toaw/nals i
Addition Neck Mwnmayfatpad
BT-474
None 0/4 0/4
Omirosen (E,) 0/4 0/4
Matrigl (M) 1/4 2/4'
M + E2 6/6 1/6k
M + fibroblasts (F)b 2/4 2/4k
SK-BR-3
None 0/4 0/4
O-shwen ND ND
Matrigel 0/10 1/10l
M+E2 ND ND
M +fibrobasts (F) 0/3 0/3
Effect of co-inoculation of tumour cell and Matige and/or
tumour-derived fibroblastswith/withoutoestrogensu lmtatinon
tunxmourtakerate. Immune-deficientmicewereinjectedwith2 x 10'celds
m both thenock and posteriormammary fatpad ND, notdetermied.
5Tumours we all >100 nmm3 and <40 mm3. bTumourdaivd
fibroblasts.
a b
livn _
rapid outgrowth of BT-474 tumours with a mean doubling
time of 9.4 ± 1.1 days. Remarkably, this was only observed
after inoculation into the neck region; only one of six
animals also developed a small, but not progressively grow-
ing, tumour in the posterior fat pad. None of the animalg
inoculated with SK-BR-3 cells (with or without hormone
supplemetation) developed a progressively growing tumour
in the neck; only one out of ten animals developed a non-
progressively growing tumour with a vohlme of 280 mm3 in
the mammary fat pad (Table I).
Because co-inoculation of various types of tumour cells
with fibroblasts has been reported to increase take rate in
immune-deficient mice, two groups of four animals were
inoculated with an equal mixture of tumour cdls and
tuLmour-derived fibroblasts in Matrigel (Table I and Figure
1c), resulting in two progressively growing BT-474 tumours.
None of the animals inoculated with SK-BR-3 cells
developed a tumour.
Effect ofinulatin dose andsite on BT-474 ntnour
formation
Tlhree groups of four oestrogenised animls were inoculated
with I0, 10 and 103 BT-474 cells premixed with Matrigel.
Animals were inoculated subcutaneously in the neck and
anterior mammary fat pad (Table H). Decreasing the number
of cells inoculated resulted in a longer latency period, but
had no effect on growth rate oftumours. Orthotopic inocula-
tion of BT-474 cells in the mammary fat pad impaired
tumour formation and growth rate compared with inocula-
tion in the neck. Even though progvel growing tumours
developed in the neck region of ten animals, none of the
tumours growing in the mammary fat pad reached a size of
more than 400mm3.
Histology andmetastatic behavour
BT-474 cells grow in small cords and idands forming a
poorly differentiated adenocrcnoma (Figure 2a). The
medium-sized nuclei are characterised by slight polymor-
phism, open chromatin stcture and small nucleoli Scat-
tered mitotic figures and cells with apoptotic morphology are
present in the tumours (Figure 2a), as wel as significant
areas with necrotic cells. BT-474 tumours are capable of
tastasising to lymph nodes (Figure 2b) and can produce
micrometastatic lesions in the lungs (Figure 2c). To prove
that lesions in the lungs contained BT474 cells, sections were
staied with an antibody recognising human keratin; as
expected, only cells in the lesions stained positive (data not
C
n=6
20 40 60 80 100 120
Time (days)
00
Flgwe I Growth of BT-474 tumours in bg-nu-xid mice: (a) without oestron su mentation; (b) with oesso suppementa-
on, (c) with Matrigw and tumour-derved fibrobasts.
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shown). BT-474 tumours show high expression of c-ErbB-2,
similar to the cell line (Figure 2d).
Characterisation ofcultured BT-474 cells and BT-474 twnours
established in immmune-deficient mice
Flow cytometric analysis (Figure 3) demonstrated that BT-
474 tumours and the BT-474 cell line had the same DNA
ploidy (DNA index = 2.52). The percentage of cells in S-
phase as determined from these histograms was almost iden-
tical in BT474 cells in vitro and in vivo, 27.2% and 24.94%
respectively. The percentage of diploid mouse cells in
tumours varied between 11% and 40%.
We used a panel of 19 antibodies to further characterise
BT-474 tumours and to detect possible phenotypic changes in
vivo compared with cultured BT-474 cells. Immunohis-
tochemical staining of frozen and paraffin sections from a
BT-474 tumour growing progressively in the neck was used
for characterisation of BT474 cells growing in vivo (Table
III). Because BT-474 adhered very weakly to various tissue
Table II Effect of inoculum size on take rate of BT-474 cells
No. ofcells Neck Mamaryfat pad
IoS 414 3/4a
104 3/4b 1/4-
103 3/4 2/4k
Effect ofBT-474 inoculum size on tumour take rate. Approximately
1 x 105, 1 x 10 or 1 x 103 cells were premixed with Matrigel and
injected in both the neck and anterior mammary fat pad of animals
receiving oestrogen supplementation. 3Tumours were all > 100 mm3
and <400 mm3. bOne animal developed two tumours
a
section slides used for immunohistochemical staining of cul-
tured cells, we used flow cytometry to determine expression
of antigens on the cells. Results of flow cytometric analysis
are shown in Figure 4. For most antigens a good correlation
exists between expression in vitro and in vivo. BT474 cells
showed high expression of PgR, c-ErbB-2 (Figures 2d and 4),
vitronectin receptor (VnR), Ep-CAM (EGP40), episialin
(MUC1), p53, Bcl-2 and transferrin receptor. Expression of
EGFR and c-Myc in vivo was very low, even though there
was a clear expression of these antigens in vitro (Figure 4).
Furthermore, 32% of cells growing in vitro expressed vimen-
tin (Figure 4), and a population of 32% of cells expressed
lower levels of Ep-CAM (Figure 4) in vitro. BT474 cells
expressed high levels of the proliferation markers Ki-67 and
PCNA both in vivo (48.47 and 99.02% positivity respectively)
and in vitro (99.29 and 97.09% positivity respectively).
Oestrogen receptor expression on BT-474 cells grown in vivo
and in vitro
We could not detect the presence of ER in BT474 tumours
using immunohistochemistry on frozen sections or on
paraffin sections using the H222 or LHl antibody. This
seemed to be in contrast with the high expression of pro-
gesterone receptor (PgR), significant growth inhibition by
anti-oestrogen in vitro (data not shown) and growth stimula-
tion by oestrogen in vivo. Subsequently, enzyme-linlked
immunoassay (EIA) using the LHl antibody and ligand-
binding asssay were performed. Again BT474 tumours were
found to be negative using both EIA and ligand-binding
assay, but the BT474 cell line, in vitro, was found to be ER
negative by EIA (3 fmol mg-' protein) and ER positive by
ligand-binding assasy (31.7 fmol mg-' protein).
c
b d
Fugwe 2 BT-474 tumour. (a) Note the presence of many mitotic figures (arrow top left), as well as many cells with an apoptotic
morphology (arrows at right offigure) (x 140). (b) Large lymph node metastasis. Note the remnant lymph node tissue in the upper
right half of the picture (arrow) ( x 140). (c) Micrometastatic ksion in the lung; the large polymorphic nuclei of the tumour cells are
clearly visibk (arrow) (x 280). (d) Immunohistochemical staining of c-ErbB-2 in a BT-474 tumour, with clear localisation of the
antigen at the cell membranes (x 140).
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Figure 3 DNA-histogram of (a) cultured BT-474 cells and (b) a
progressively growing BT-474 tumour. DNA ploidy was deter-
mined using chicken red blood cells (CRBC) as a reference.
Cultured BT-474 cells and BT-474 cells isolated from a tumour
had an identical DNA index of 2.52. The percentage of mouse
stroma cells present in the tumour was 7%.
Cell cycle kinetics: comparison of tumours growing in the neck
and in the mammary fat pad
We investigated whether differences in growth rate between
tumours growing in the neck and mammary fat pad were
correlated with differences in growth fraction or apoptotic
fraction. These fractions were determined by immunohis-
tochemistry with the MIB-1 antibody against Ki-67 and in
situ end-labelling of DNA strand breaks respectively. Growth
fractions were quantitated by counting a total of 1000 cells in
every section. Apoptotic fractions were determined with an
automated image analysis system. Surprisingly, no significant
differences were found in growth fractions or apoptotic frac-
tions of tumours growing in the neck compared with the
mammary fat pad of the same mouse (Table IV).
Dimss
While useful xenotransplantation models have been deve-
loped for other primary tumours Cornil et al., 1989; Fu et
al., 1991, 1992), this approach remains very difficult for
primary hormone-dependent breast cancer. The only hor-
mone-responsive cell lines for which successful xenotrans-
plantation has been described are the MCF-7, ZR-75-1 and
T-47D cell lines (Shafie and Liotta, 1980; Leung and Shiu,
1981; Weckbecker et al., 1992; Yue and Brodie, 1993), which
are all derived from pleural effusions. In this study we show
that a hormone-responsive cell line derived from a primary
breast carcinoma, BT-474 (Lasfargues et al., 1978), can grow
in bg-nu-xid mice when cells are co-inoculated with Matrigel.
The increase in tumorigenicity caused by mixing cells with
Matrigel is so dramatic that even inoculation of approx-
Table m Characterisation of BT-474 tumours using immuno-
histochemistry
Frozen
Antigen Clone Isotype sections Cell line'
ER H222 IgGI - ND
ER LHI IgGI - ND
PgR 1A6 IgGI +3 +4
EGFR 225 IgGI _ +2
c-ErbB2 3b5 IgGI +5 +4
MA, GOH3 IgGl +2 +1
MA B6H12.2 IgGI +5 +4
ICAM-1 LB2 IgG2b - -
HLA A,B,C W6/32 IgG2a +2 +2
Ep-CAM (323-A3) 17.1a IgGI +5 +5
Ep-CAM (BMA180) 17.1a IgG3 +5 +5,/+2b
Episialin (MAM6) GPI.4 IgGI +3 +4
Keratin (total) Clone 80 IgGI +3c ND
Vimentin V9 IgGI - +1/+4b
p53 Do7 IgG2b +4 +2
Bcl-2 Clone 124 IgGI +3 +3
c-Myc 9b7 IgGI - +2
Transferrin receptor PAL-Mi IgGI +3 +5
Ki-67d MIB-l IgGI ND
PCNAd PC1O IgG2a ND
'Summarised from flow cytometric data (Figure 4). b32% of the cells
expressed lower or higher levels respectively. 9Determined on paraffin
sections. dResults stated in text. ND, not determined. Antigen
expression in frozen sections and cell lines was scored semiquan-
titatively, scores ranging from negative (-) to high expression ( + 5). +1
is +, +5is +++++.
imately 1000 cells results in formation of tumours. Because
the main component of Matrigel is the basement membrane
protein laminin, the capability of BT-474 cells to bind to this
protien using receptors such as 4f4-integrin, is likely to
contribute to this effect of Matrigel on tumorigenicity. It has
been hypothesised that Matrigel, and especially proteolytic
fragments of laminin, plays a role in stimulating angiogenesis
(Fridman et al., 1992), and therefore is responsible for the
outgrowth of inoculated tumour cells. Furthermore, matrix-
associated growth factors (e.g. fibroblast growth factors; tis-
sue plasminogen activator) within Matrigel may also enhance
tumorigemncity.
Although it does not seem to be an absolute requirement,
oestrogen supplementation greatly enhances tumorigenicity.
Removal of oestrogen pellets from animals with established
BT-474 tumours resulted in tumour regression accompanied
by marked apoptosis (GT Colbern, personal communica-
tion), indicating that BT474 tumours are dependent on
oestrogen for their growth. Similarly, oestrogen-dependent
MCF-7 cells have been reported to retain the ability to
activate a programmed cell death pathway following oest-
rogen ablation (Kyprianou et al., 1991). Our findings are
therefore consistent with the hypothesis that oestrogen not
only stimulates proliferation, but may also serve as a strong
survival factor for breast cancer cells. Addition of fibroblasts,
reported to increase tumongemcity of several cell lines in
immune-deficient mice (Horgan et al., 1987; Chung, 1991;
Noel et al., 1992), had no additional effect. A number of
reports described an increased take rate of breast tumour
cells after inoculation into the mammary fat pad (Miller et
al., 1981; White et al., 1982; Miller and Mclnerney, 1988;
Price et al., 1990; Elliott et al., 1992), but in the present study
we observed a higher take and growth rate of BT-474 cells in
the neck region than in the mammary fat pad. Because no
difference was observed in expression of the cellular prolifera-
tion marker Ki-67 between two tumours derived from the
neck and mammary fat pad respectively, a difference in cell
loss was likely to be responsible for this phenomenon. How-
ever, we did not find a significant difference in the number of
apoptotic cells detected by in situ end-labelling of DNA
strand breaks, making it difficult to explain observed
differences in tumour growth rate. We cannot exclude the
possibility that physical differences such as subcutaneous
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Fugwe 4 Expression of 15 antigens on BT-474 cells in vitro, as detrmined by flow cytometry. Dotted lines represent control
samples.
Table IV Growth fractions and apoptotic fractions in the neck and
mammary fat pad
Mouse Twnour site Growthfraction (%) Apoptotic area (%)
1 Neck 48.47 0.418
mfp'
22 Neck
mfp
44.14
49.7
49.1
0.414
0.883
0.986
'Tumour growing in the mammary fat pad. Growth fracton was
defined as the percentage of Ki-67 positive cells. A total of 1000 cells
werecounted ineverysection. Apoptoticfractionwasdefined asareain
the sections staining brown after in situ end-labelling of DNA stand
break.s.
space and blood supply have a negative effect on tumour
growth in the mammary fat pad.
In vivo BT-474 cells grow as a poorly differentiated
adenocarcinoma, metastasising to lymph nodes and capable
of forming micrometastatic lesions in lung. No major
differences were seen in histology ofprimary BT-474 tumours
and lymph node metastases. Flow cytometric analysis of the
DNA content of BT-474 cells demonstrated the DNA ploidy
of tumours growing in bg-nu-xid mice to be identical to that
of the cell line. To determine if the phenotype had changed
and to characterise BT-474 tumours further, we evaluated the
presence of various markers. For most antigens tested, a
good correlation between expression in vitro and in vivo was
found, indicating that no major phenotypic changes had
occurred. Because tumours were not routinely passaged in
immune-deficient mice, no data are available on long-term
stability of BT-474 tumours. However, the high tumori-
genicity of BT-474 cells in this model allows induction of
many tumours from the same passage of cultured cells if a
sufficient number of cells are stored in liquid nitrogen. Addi-
tional advantages of inoculation ofcultured cells are constant
inoculum size and the absence of heterogeneity caused by
inter- and/or intra-tumour heterogeneity often present in pas-
saged tumours.
The BT-474 cell line was originally reported to be ER
negative, but more recent studies have reported it to be ER
positive, as detected by radioligand-binding assay (Koga et
al., 1990; Lupu and Lippman, 1993). In our laboratory we
were not able to detect ER expression on BT-474 tumours
using immunohistochemistry, although the biological be-
haviour of BT-474 cells in vivo and in vitro was oestrogen
responsive. Subsequently, a ligand-binding assay clearly dem-
onstrated the presence of intermediate levels of ER in the
BT-474 cell line, while an enzyme immunoassay performed
on the same samples faied to detect significant amounts of
ER. The low ER expression detected in tumour using the
ligand-binding assay may have been caused by high level of
endogenous oestrogen owing to hormone supplementation.
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Recent studies have demonstrated, in both breast tumour cell
lnes and primary breast tumours, presene of variant ER
mRNAs, probably resulting from alternative splcing (Castes
et al., 1993). Tlhrefore, a possible explanation for the
conflicting results in our study may be that, although ER is
functional, it cannot be detected immunohistochemically
owing to an alteration ofthe epitope recognised by the H222
and LHI antibodies. The functionality of the ER is dearly
demonstrated by sensitivity of this cell ine to anti-oestogens
(data not shown), by high expression of PgR, which is
thought to be regulated by oestrogen (Horwitz, 1993), and by
tumour gression after oestrogen deprivation (GT Colbem,
personal communication).
A remarkable feature of the BT-474 cell line is its overex-
pression of c-erbB-2, an oncogene overexpressed in 30% of
human breast cancers (Elliedge et al., 1992), almost half of
which are also ER positive (Pavelic et al., 1992; Hynes,
1993). Interestingly, evidence is increasing that c-erbB-2
overexpression is associated with tumour cell resistance to
NK-cell activity as well as treatment with anti-oestrgens
(Hudziak et al., 1988; Hynes, 1993; Lichtenstein et al., 1993;
Wiltschke et al., 1994). In this context it is interesting to note
that studies are emerging demonstrating a negative feedback
loop between sign transduction through ER and c-ErbB-2
(Warri et al., 1991; Dati et al., 1993; Read et al., 1993).
Ligation of ER with oestrogen inhibits the expression of
c-ErbB-2. In contrast, the c-ErbB-2 ligands gp3O and p75
have been reported to down-regulate in a dose-dependent
manner the expression of ER in BT474 and MCF-7 cels,
when using hormone-depeted medium (Colomer et al.,
1992). Moreover, growth of BT474 cells has been reported
to be stimulated by gp3O in oestrogen-depleted and inhibited
in oestrogen-suplemented medium (Grunt et al., 1994). Sig-
nal transduction via c-ErbB-2 may thus be responsible for
escape from anti-oestrogen treatment in a simila way as has
been hypothesised for other growth factor receptors, such as
epidermal growth factor receptor (EGFR) and insulin-like
growth factor I (IGF-I) recptor (Arteaga et al., 1989, Mur-
phy and Dotzlaw, 1989; Gill et al., 1991; Ignar-Trowbridge et
al., 1992; Long et al., 1992). Also, down-regulation of ER
mediated by c-ErbB-2 ligands may dcrease the availability
of ER in vivo, giving a possible explanation for our failure to
detect ER in BT474 tumours.
EGFR could be clearly detected in BT-474 cell mono-
layers, but not in frozen sections from solid tumours. A
similar discrepancy was found for the presence of c-Myc
protein, although this could have been caused by rapid deg-
radation of this protein after excision of tumours (Hann and
Eisenman, 1984). The aJ4rintegrin was present in frozen
sections, but could not be detected in cultured BT474 cells
using flow cytometry.
As ited by various proliferation markers and by high
S-phas dete by DNA flow cytometry, BT-474 tumours
show high proliferative activity. However, compared with the
number of proliferating cells, the doubling time of BT474
tumours was relatively long, inditing the existenm ofa high
rate of cell turnover. Use of in situ end-labelling of
fragmented DNA revealed that many cells displayed the
classic morphology of apoptosis, with chromatin condensa-
don, nuclear fragmentation and cell shinage. Other cells
had a more pycnotic appearance with round, condensed
nuclei and little cytoplasm. Most strikgly, some apoptotic
cells were engulfed by other tumour cells in a process known
as tumour emperpoesis (Tsunoda et al., 1992).
The high rate ofapoptosis, even in rapidly growing BT-474
tumours with high PCNA and Ki-67 indices, prompted us to
analyse some factors that could be involved in this process.
The product of the c-myc oncogene has been reported to
drive both proliferation and apoptosis (Evan and Littlewood,
1993), whereas increased expression of the bcl-2 gene could
possibly enhance survival of cells otherwise doomed to die.
In many cell types, Bcl-2 has been reported to counteract the
induction of cell death by various treatments (Kamesaki et
al., 1993; Reed, 1994), including apoptosis induced by
overexpression of c-myc (Bissonnette et al., 1992). The
intermediate lvel of Bcl-2 expression in BT-474 cells raises
the question of whether the level of Bcl-2 is not sufficient to
inhibit apoptosis effectively in BT-474 tumours, or whether
this type of apoptotic cell death is simply not modulated by
Bcl-2, but by one of its recently discovered variants (Boise et
al., 1993; Oltvai et al., 1993).
Another factor possibly involved in the induction of apop-
tosis is the product of the p53 tumour-suppressor gene.
Mounting evidence shows that wild-type p53 protein is
important for the induction of apoptosis in cells with a
signifant amount of DNA damage, e.g. as a result of X-
radiation or chemotherapy (Lowe et al., 1993). Moreover,
wild-type p53 has recently been reported to play a role in the
induction of apoptosis by growth factor deprivation (Zhu et
al., 1994), possibly by down-regulating Bcl-2 and up-
regulating Bax protein expresson (Haldar et al., 1994;
Miyashita et al., 1994). It has been reported that BT-474 cells
bear a missense mutation in the p53 gene and show loss of
heterozygosity (Bartek et al., 1990) at this locus. The effect of
absence ofwild-type p53 in this cell lie on cell death regula-
tion therefore needs further clarification.
In conclusion, BT-474 cells offer an interesting opportunity
to investigate various aspects of growth regulation and
dissemination in oestrogen-dependent breast cancer. More-
over, the capacity of this cell lne to grow and metastasise in
immune-deficient mice in combination with high expression
ofoell-surface proteins such as c-ErbB-2 and esialin make it
a potentially usefu in vitro/in vivo model for research in
immune therapy.
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